Tip:
Highlight text to annotate it
X
>> SO, ZYBODIES ARE
ANTIBODY-BASED DRUGS AND
ANTIBODIES, AS YOU KNOW, ARE
PROTEINS THAT ARE NATURALLY
OCCURRING IN THE BODY, IN HUMAN
BODIES, IN ALL ANIMALS, ALL
MAMMALS INCLUDING--ESPECIALLY,
AND THEY--THEY'RE--THEY'RE--
THEY'RE SMALL PROTEINS THAT ARE
MADE FROM WHITE BLOOD CELLS AND
B CELLS TO BE SPECIFIC--AND
THESE ANTIBODIES ARE INVOLVED IN
REGULATING THE IMMUNE SYSTEM AND
RESPONSIBLE FOR--FOR PLAYING A
ROLE IN DESTROYING CANCER CELLS,
IDENTIFYING AND ATTACKING
PATHOGENS, INFECTIOUS DISEASES,
ET CETERA.
AND THROUGH INNOVATION AND
SCIENCE, NOT WE BUT THE
COLLECTIVELY SCIENTIFIC
COMMUNITY HAS BEEN ABLE TO
CAPITALIZE ON THIS ANTIBODY
STRUCTURE AND DEVELOP NEW
THERAPEUTICS TO TREAT DISEASES,
ALL KINDS OF DISEASES, AND
THEY'VE BEEN VERY SUCCESSFUL.
AND WHAT WE'RE DOING WITH OUR
ZYBODIES, WE ARE THE NEXT
GENERATION OF ANTIBODIES.
AND THESE ZYBODIES ARE--ENABLE
YOU TO COMBINE MULTIPLE
ANTIBODIES INTO ONE DRUG OR
THE--OR THE PATHWAYS OR THE
TARGETING OF MULTIPLE
ANTIBODIES, INTO ONE--ONE
THERAPEUTIC DRUG.
AND THE CLEAR ADVANTAGE OF THAT
IS THE ABILITY TO CUT COST, HAVE
ONE DRUG THAT HITS MULTIPLE
TARGETS SIMULTANEOUSLY.
SO, YOU CAN THINK OF THREE OR
FOUR OF THE MOST SUCCESSFUL
DRUGS, AND BEING ABLE TO COMBINE
THOSE INTO ONE DRUG HAS
A SIGNIFICANT COST ADVANTAGE
TO IT.
BUT WHAT GETS US MOST EXCITED,
AND PARTICULARLY THE SCIENTIST,
IS THE IDEA THAT NOW YOU COULD
POTENTIALLY TARGET DISEASE OR
IMPACT DISEASE LIKE YOU HAVE NOT
BEEN ABLE TO DO IT BECAUSE
YOU'RE HITTING MULTIPLE TARGETS
SIMULTANEOUSLY.